期刊文献+

乙型肝炎表面抗原清除后与疾病长期临床结局的关系 被引量:1

Relationship between Hepatitis B Surface Antigen Clearance and Long-Term Clinical Outcomes
下载PDF
导出
摘要 早在《2015慢性乙型肝炎防治指南》中已明确指出,慢性乙型肝炎的临床治愈已被作为理想的治疗终点。无论是表面抗原自发清除还是通过抗病毒治疗后实现的表面抗原清除,一部分慢乙肝患者已经实现了乙肝的临床治愈,但乙肝表面抗原清除并不是一劳永逸的,HBsAg清除的持久性及临床结局的改善相关研究有限,本文旨在就血清HBsAg清除后的长期临床结局行综述。 As already stated in the 2015 Guidelines for the Prevention and Treatment of Chronic Hepatitis B, clinical cure of chronic hepatitis B has been regarded as the ideal therapeutic endpoint. Some pa-tients with chronic hepatitis B have achieved clinical cure of hepatitis B, whether it is spontaneous clearance of surface antigen or the clearance of surface antigen after antiviral treatment. However, hepatitis B surface antigen clearance is not permanent and relevant studies on the persistence of HBsAg clearance and improvement of clinical outcome are limited. This article aims to review the long-term clinical outcomes after serum HBsAg clearance.
出处 《临床医学进展》 2023年第3期4123-4128,共6页 Advances in Clinical Medicine
  • 相关文献

参考文献2

二级参考文献43

  • 1Peng Hu,Jia Shang,Wenhong Zhang,Guozhong Gong,Yongguo Li,Xinyue Chen,Jianning Jiang,Qing Xie,Xiaoguang Dou,Yongtao Sun,Yufang Li,Yingxia Liu,Guozhen Liu,Dewen Mao,Xiaoling Chi,Hong Tang,Xiaoou Li,Yao Xie,Xiaoping Chen,Jiaji Jiang,Ping Zhao,Jinlin Hou,Zhiliang Gao,Huimin Fan,Jiguang Ding,Dazhi Zhang,Hong Ren.HBsAg Loss with Peg-interferon Alfa-2a in Hepatitis B Patients with Partial Response to Nucleos(t)ide Analog:New Switch Study[J].Journal of Clinical and Translational Hepatology,2018,6(1):25-34. 被引量:93
  • 2KWON H, LOKAS. HepatitisBtherapy[J]. NatRevGastro- enterol Nepatol, 2011, 8(5) : 275 -284.
  • 3SONNEVELD M J, JANSSEN HL. Chronic hepatitis B: peginter- feron or nucleos(t) ide analogues? [ J ]. Liver Int, 2011, 31 ( Suppl 1 ) : 78 -84.
  • 4KIM SS, CHEONG JY, CHO SW. Current nucleos(t)ide an- alogue therapy for chronic hepatitis B[ J]. Gut Liver, 2011,5 (2) : 278 -287.
  • 5MUTIMER D, NAOUMOV N, HONKOOP P, et al. Combina- tion alpha - interferon and lamivudine therapy for alpha - in- terferon- resistant chronic hepatitis B infection: results of a pilot study[J]. J Hepatol, 1998, 28(6) : 923 -929.
  • 6BARBARO G, ZECHINI F, PELLICELLI AM, et al. Long - term efficacy of interferon alpha -2b and lamivudine in com- bination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial[J]. J Hepatol, 2001, 35(3): 406 -411.
  • 7CAO ZH, MA LN, ZHANG HW, et al. Extended treatment with peginterferon -2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion[ J]. J Dig Dis, 2013, 14(8) : 446 -450.
  • 8LAU GK, PIRATVISUTH T, LUO KX, et al. Peginterferon Alfa - 2a, lamivudine, and the combination for HBeAg -positive chronic hepatitis B[J]. N Engl J Med, 2005, 352(26): 2682 - 2695.
  • 9JANSSEN HL, van ZONNEVELD M, SENTURK H, et al. Pe- gylated interferon alfa -2b alone or in combination with lami- vudine for HBeAg- positive chronic hepatitis B: a random- isedtrial[J]. Lancet, 2005, 365(9454): 123 -129.
  • 10MARCELLIN P, LAU GK, BONINO F, et al. Peginterferon al- fa -2a alone, lamivudine alone, and the two in combination in patients with HBeAg - negative chronic hepatitis B [ J ]. N Engl J Med, 2004, 351 (12) : 1206 -1217.

共引文献13

同被引文献9

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部